MaltSci 麦伴科研

Appearance

Popular Reports / Clinical Medicine

This report is written by MaltSci based on the latest literature and research findings

What are the mechanisms of metabolic syndrome? ​

Abstract ​

Metabolic syndrome (MetS) is a complex disorder characterized by a cluster of interrelated conditions, including obesity, insulin resistance, dyslipidemia, and hypertension, which significantly elevate the risk of cardiovascular diseases and type 2 diabetes. The rising prevalence of MetS, largely driven by lifestyle factors such as poor diet and physical inactivity, poses a major public health challenge. This review aims to elucidate the underlying mechanisms of MetS, focusing on the roles of insulin resistance, chronic inflammation, and dyslipidemia, alongside the contributions of genetic and epigenetic factors. Insulin resistance emerges as a central feature, exacerbated by obesity and low-grade inflammation, leading to metabolic dysregulation. The interplay between dietary patterns, physical activity, and metabolic health highlights the need for comprehensive lifestyle interventions. Furthermore, the gut microbiome's influence on metabolic processes and the effects of hormonal changes present exciting new research avenues. Understanding these multifactorial mechanisms is crucial for developing effective prevention and treatment strategies for MetS. This review synthesizes current findings, emphasizing the importance of early detection and intervention in addressing this growing public health concern.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Overview of Metabolic Syndrome
    • 2.1 Definition and Diagnostic Criteria
    • 2.2 Prevalence and Public Health Impact
  • 3 Pathophysiological Mechanisms
    • 3.1 Insulin Resistance
    • 3.2 Inflammation and Immune Response
    • 3.3 Dyslipidemia and Lipid Metabolism
  • 4 Role of Lifestyle Factors
    • 4.1 Diet and Nutrition
    • 4.2 Physical Activity and Sedentary Behavior
    • 4.3 Obesity and Body Composition
  • 5 Genetic and Epigenetic Influences
    • 5.1 Genetic Predisposition
    • 5.2 Epigenetic Modifications and Environmental Interactions
  • 6 Emerging Research Areas
    • 6.1 Gut Microbiome and Metabolic Health
    • 6.2 Hormonal Regulation and Endocrine Disruptors
  • 7 Summary

1 Introduction ​

Metabolic syndrome (MetS) represents a complex and multifaceted disorder characterized by a cluster of interrelated conditions that significantly elevate the risk of cardiovascular diseases, stroke, and type 2 diabetes. The increasing prevalence of MetS has emerged as a pressing public health concern globally, driven by lifestyle factors such as obesity, physical inactivity, and poor dietary habits. As these risk factors become more prevalent, understanding the underlying mechanisms of MetS is essential for developing effective prevention and treatment strategies. This review aims to elucidate the intricate interplay of genetic, environmental, and biological factors contributing to the pathogenesis of MetS, with a particular focus on insulin resistance, inflammation, dyslipidemia, and the role of the gut microbiome and hormonal changes.

Research into the mechanisms of MetS has revealed that it is not merely a collection of symptoms but rather a distinct pathological state driven by a convergence of metabolic and physiological alterations. The interplay between obesity and insulin resistance is particularly noteworthy, as these factors are closely linked to chronic low-grade inflammation and dyslipidemia, both of which exacerbate the risk of developing more severe health issues, including type 2 diabetes and cardiovascular diseases [1][2]. Furthermore, the relationship between dietary patterns, physical activity, and metabolic health is increasingly recognized as a critical area for intervention [3][4]. Understanding these mechanisms is crucial, as they can inform both public health policies and clinical practices aimed at mitigating the impact of MetS.

Current research has made significant strides in identifying the pathophysiological mechanisms underlying MetS. Insulin resistance has been identified as a central feature, with studies demonstrating its role in the development of associated conditions such as hypertension and dyslipidemia [2][5]. Inflammation, driven by both genetic predispositions and environmental factors, plays a pivotal role in the progression of MetS, contributing to the dysregulation of metabolic processes [6][7]. Dyslipidemia, characterized by abnormal lipid levels, further complicates the metabolic landscape, leading to increased cardiovascular risk [7][8]. This review will delve into these pathophysiological mechanisms in detail, highlighting their interconnections and implications for health.

In addition to biological mechanisms, lifestyle factors such as diet, physical activity, and obesity are critical determinants of MetS. Research indicates that dietary choices, particularly those high in saturated fats and sugars, can significantly influence insulin sensitivity and inflammatory responses [3][9]. Moreover, physical inactivity has been linked to increased visceral fat accumulation, further exacerbating metabolic dysregulation [1][4]. This review will explore the role of these lifestyle factors in the context of MetS, emphasizing the need for comprehensive lifestyle interventions to combat this growing epidemic.

The genetic and epigenetic influences on MetS are also of paramount importance. Emerging evidence suggests that genetic predispositions interact with environmental factors to shape an individual's metabolic phenotype [7][10]. Epigenetic modifications, driven by dietary and lifestyle factors, can alter gene expression without changing the DNA sequence, thereby influencing the risk of developing MetS [7][10]. This review will address these genetic and epigenetic dimensions, underscoring their significance in understanding the complex etiology of MetS.

Emerging research areas, particularly the role of the gut microbiome and hormonal regulation, offer exciting new avenues for understanding MetS. The gut microbiome has been implicated in the regulation of metabolic processes and the modulation of inflammation, suggesting that interventions targeting gut health may provide novel therapeutic strategies [7][11]. Hormonal changes, including those associated with stress and metabolic dysfunction, further complicate the hormonal landscape in individuals with MetS [7][7]. This review will highlight these innovative research directions, which hold promise for enhancing our understanding of MetS and informing future therapeutic approaches.

In summary, this review will provide a comprehensive overview of the mechanisms underlying metabolic syndrome, organized into distinct sections that cover the definition and prevalence of MetS, pathophysiological mechanisms, lifestyle factors, genetic influences, and emerging research areas. By synthesizing current research findings, this report aims to contribute to a deeper understanding of MetS and its multifactorial nature, paving the way for future studies and clinical applications. The ultimate goal is to highlight the importance of early detection and intervention, emphasizing the need for a multidisciplinary approach to address this growing public health challenge effectively.

2 Overview of Metabolic Syndrome ​

2.1 Definition and Diagnostic Criteria ​

Metabolic syndrome (MetS) is a complex and multifactorial disorder characterized by a cluster of metabolic abnormalities that significantly increase the risk of cardiovascular disease and type 2 diabetes. The mechanisms underlying MetS involve a combination of genetic, environmental, and lifestyle factors that interact in intricate ways.

One of the primary mechanisms is insulin resistance, which is a state where the body's cells become less responsive to insulin, leading to elevated blood glucose levels. Insulin resistance is closely associated with obesity, particularly visceral obesity, which contributes to a pro-inflammatory state due to the secretion of various adipokines from adipose tissue. This inflammatory response is mediated by molecules of hepatic, vascular, and immunologic origin, which play significant roles in the pathogenesis of MetS [1].

Additionally, overnutrition and physical inactivity have been identified as key contributors to the development of MetS. These factors can lead to mitochondrial oxidative stress, which disrupts normal metabolic processes and exacerbates insulin resistance [5]. The interaction between chronic overnutrition and genetic predisposition results in a phenotype characterized by metabolic dysregulation, which is evident in various components of MetS, including hypertension, dyslipidemia, and glucose intolerance [5].

The role of inflammation is further emphasized by the activation of the nuclear factor kappa B (NF-κB) pathway, which is triggered by overnutrition-induced cellular stress. This pathway is critical in mediating the inflammatory responses that contribute to the development of obesity, insulin resistance, and ultimately, MetS [6].

Moreover, lifestyle factors such as dietary habits and physical activity levels significantly influence the risk of developing MetS. The interplay between diet and genetic factors can modulate inflammatory markers, thus impacting the progression of metabolic abnormalities [12].

Epigenetic modifications also play a role in the pathogenesis of MetS, as they can alter gene expression without changing the DNA sequence, contributing to the development of insulin resistance and other metabolic disturbances [10].

Furthermore, maternal conditions during pregnancy, such as nutrient imbalance and exposure to environmental toxins, can program offspring for the development of MetS later in life, illustrating the importance of early-life factors in the disease's etiology [11].

In summary, the mechanisms of metabolic syndrome are diverse and interconnected, involving insulin resistance, obesity, inflammation, mitochondrial dysfunction, genetic and epigenetic factors, and lifestyle influences. Understanding these mechanisms is crucial for developing effective prevention and treatment strategies for MetS and its associated complications.

2.2 Prevalence and Public Health Impact ​

Metabolic syndrome (MetS) is characterized by a cluster of metabolic abnormalities, including central obesity, hypertension, dyslipidemia, and insulin resistance, which significantly increase the risk of cardiovascular disease and type 2 diabetes. The mechanisms underlying metabolic syndrome are multifactorial, involving a complex interplay of genetic, environmental, and lifestyle factors.

One of the primary mechanisms contributing to the development of metabolic syndrome is insulin resistance, which occurs when cells in the body become less responsive to insulin, leading to elevated blood glucose levels. This condition is often exacerbated by obesity, particularly visceral adiposity, which is associated with increased levels of pro-inflammatory cytokines and other factors that contribute to metabolic dysregulation [1][2].

Chronic overnutrition and lack of physical activity are significant contributors to the rising prevalence of metabolic syndrome, particularly in developed countries. Overnutrition can trigger intracellular stresses that lead to inflammatory changes, primarily mediated by the pro-inflammatory nuclear factor kappa B (NF-κB) pathway. This pathway plays a critical role in translating nutritional excess into neuroendocrine dysregulation, affecting energy balance and glucose metabolism [6].

Furthermore, genetic factors and epigenetic modifications also play essential roles in the pathogenesis of metabolic syndrome. Studies have shown that dietary patterns and genetic predispositions can interact to modulate inflammatory responses, which are integral to the progression of metabolic syndrome [10][12]. For instance, the dysregulation of glucose and lipid metabolism in adipose tissue, liver, and muscle is often influenced by both genetic makeup and lifestyle choices, leading to a spectrum of metabolic abnormalities [7].

The mechanisms of metabolic syndrome are also linked to hormonal and neuroendocrine dysregulations. For example, the renin-angiotensin-aldosterone system and sympathetic nervous system overactivity are often implicated in the pathophysiology of hypertension associated with metabolic syndrome [2][13]. Moreover, the secretion of adipokines from visceral fat can further exacerbate insulin resistance and contribute to a pro-inflammatory state [1].

In terms of public health impact, the prevalence of metabolic syndrome is alarmingly high, with significant implications for healthcare systems worldwide. It is associated with increased morbidity and mortality from cardiovascular diseases and type 2 diabetes, making it a critical area of focus for prevention and intervention strategies. The rising incidence of obesity, particularly in younger populations, highlights the urgent need for public health initiatives aimed at promoting healthier lifestyles, including diet and physical activity [4][7].

In summary, the mechanisms of metabolic syndrome involve a complex interplay of insulin resistance, obesity-related inflammation, genetic predispositions, and neuroendocrine dysregulation, all of which contribute to its high prevalence and significant public health implications. Addressing these factors through lifestyle interventions and targeted therapies is crucial for managing and preventing metabolic syndrome and its associated health risks.

3 Pathophysiological Mechanisms ​

3.1 Insulin Resistance ​

Metabolic syndrome (MS) is characterized by a cluster of metabolic abnormalities, with insulin resistance being a central feature. The pathophysiological mechanisms underlying metabolic syndrome are complex and involve various interrelated factors, primarily revolving around insulin resistance, which leads to multiple adverse health outcomes.

Insulin resistance is defined as a state of reduced responsiveness of insulin-targeting tissues, such as muscle, fat, and liver, to physiological levels of insulin. This condition results in impaired insulin action, which manifests as abnormalities in glucose metabolism, including decreased peripheral glucose disposal and increased hepatic glucose output, particularly in the fasting state. The consequence of these metabolic disturbances is a progressive increase in circulating glucose levels, which in turn affects insulin secretion and contributes to a pro-inflammatory state and dyslipidemia, characterized by low levels of high-density lipoprotein cholesterol (HDL-C) and elevated triglycerides and small dense low-density lipoprotein (LDL) particles [14].

The mechanisms of insulin resistance are multifactorial. One primary factor is ectopic fat deposition, which occurs when excess fatty acids accumulate in non-adipose tissues, such as the liver and skeletal muscle. This accumulation can impair insulin signaling pathways, specifically through the inhibition of insulin receptor substrate-1 (IRS-1) and associated signaling molecules, thereby disrupting normal glucose transport and metabolism [15][16]. Furthermore, the inflammatory response induced by oxidative stress and the presence of excess fatty acids can exacerbate insulin resistance by altering the function of key transcription factors involved in glucose metabolism [17].

Genetic factors also play a significant role in the pathogenesis of insulin resistance and metabolic syndrome. Genome-wide association studies have identified various genetic variants associated with insulin resistance, many of which are involved in glucose and lipid metabolism [18]. These genetic predispositions, combined with environmental factors such as diet and physical inactivity, create a conducive environment for the development of metabolic syndrome [19].

Moreover, insulin resistance is often accompanied by a state of metabolic inflammation, which further complicates its pathophysiology. This inflammatory response can be triggered by excessive oxidative metabolism, leading to a compensatory reduction in insulin action as a protective mechanism [17]. The interaction between insulin resistance, obesity, and inflammation is a crucial aspect of metabolic syndrome, highlighting the importance of addressing each component to mitigate the overall risk of cardiovascular disease and other related health issues [20].

In summary, the mechanisms of metabolic syndrome are primarily centered around insulin resistance, which is influenced by a combination of genetic, environmental, and inflammatory factors. The interplay of these elements contributes to the metabolic abnormalities characteristic of the syndrome, necessitating a comprehensive approach to treatment and management that targets each contributing factor.

3.2 Inflammation and Immune Response ​

Metabolic syndrome is characterized by a cluster of metabolic abnormalities, including central obesity, insulin resistance, hypertension, and dyslipidemia, which significantly increase the risk of cardiovascular diseases and type 2 diabetes. The underlying mechanisms of metabolic syndrome are complex and multifactorial, with inflammation and immune responses playing a crucial role.

Chronic low-grade inflammation is a hallmark of metabolic syndrome, which is often initiated by overnutrition and obesity. This inflammatory response is mediated by the activation of innate immune cells, particularly macrophages, which infiltrate adipose tissue. In obesity, adipocytes undergo hypertrophy, leading to the recruitment of pro-inflammatory M1 macrophages. These macrophages produce pro-inflammatory cytokines, further perpetuating the inflammatory cycle and recruiting additional immune cells, thereby exacerbating the inflammatory response in adipose tissue [21].

The hypothalamus also plays a central role in the neuroinflammatory processes associated with metabolic syndrome. Inflammatory changes in the hypothalamus, triggered by overnutrition, involve the activation of pro-inflammatory pathways such as the IκB kinase-β (IKKβ) and nuclear factor kappa B (NF-κB) signaling pathways. These pathways are crucial for the regulation of inflammation and energy homeostasis. The resultant neuroinflammation leads to dysregulation of neuroendocrine functions, which can manifest as insulin resistance, altered glucose metabolism, and cardiovascular dysfunction [22].

Moreover, the phenomenon known as "metaflammation" describes the sterile metabolic inflammation that occurs in the absence of infection. This persistent inflammation results from the failure of the immune system to resolve the inflammatory response effectively, leading to immune senescence and further progression of metabolic disorders [23]. In metabolic syndrome, the interplay between aberrant metabolism and immune responses can create a vicious cycle, wherein metabolic dysfunction exacerbates inflammation, and chronic inflammation, in turn, aggravates metabolic disturbances [6].

The inflammasome, particularly the NLRP3 inflammasome, has also been identified as a key player in the inflammatory mechanisms underlying metabolic syndrome. It is activated in response to metabolic stress and contributes to the release of pro-inflammatory cytokines such as interleukin-1β (IL-1β). This cytokine promotes insulin resistance and other metabolic disturbances, indicating that inflammasome signaling is intricately linked to the pathogenesis of metabolic disorders [24].

In summary, the pathophysiological mechanisms of metabolic syndrome are significantly influenced by inflammation and immune responses. Chronic low-grade inflammation, driven by the activation of immune cells and the dysregulation of inflammatory pathways, plays a pivotal role in the development and progression of metabolic abnormalities associated with metabolic syndrome. Understanding these mechanisms is crucial for developing targeted therapeutic strategies aimed at mitigating the effects of inflammation and improving metabolic health.

3.3 Dyslipidemia and Lipid Metabolism ​

Metabolic syndrome is characterized by a constellation of metabolic and vascular abnormalities, prominently including dyslipidemia, which significantly contributes to its pathophysiology. Dyslipidemia in metabolic syndrome is primarily defined by the overproduction of large triglyceride-rich very-low-density lipoproteins (VLDL), low levels of high-density lipoprotein (HDL) cholesterol, and elevated levels of small, dense low-density lipoprotein (LDL) cholesterol particles. This lipid abnormality is closely associated with insulin resistance, which plays a critical role in triglyceride metabolism and the overall development of type 2 diabetes mellitus [25].

The mechanisms underlying dyslipidemia in metabolic syndrome involve several key processes. Firstly, insulin resistance leads to impaired insulin signaling, which disrupts normal lipid metabolism. The hepatic overproduction of large VLDL is a consequence of this insulin resistance, which in turn contributes to the dyslipidemic profile observed in affected individuals [25]. Furthermore, dysfunctional lipid metabolism is exacerbated by dietary factors, particularly the consumption of high-caloric, high-fat, and high-carbohydrate diets. These dietary habits have been linked to altered gene expression related to lipolysis and lipogenesis, impacting plasma lipid levels and adipose tissue metabolism [26].

MicroRNAs (miRNAs) have emerged as critical regulators in the context of metabolic syndrome. They modulate the expression of genes involved in lipid synthesis, mitochondrial fatty acid oxidation, and lipoprotein assembly. Dysregulation of specific miRNAs can lead to mitochondrial dysfunction and endoplasmic reticulum (ER) stress, both of which are implicated in the overproduction of VLDL and altered HDL biogenesis [27]. This dyslipoproteinemia is a hallmark of metabolic syndrome, highlighting the importance of miRNAs in the lipid metabolic pathways [28].

Additionally, chronic inflammation, often associated with visceral obesity, plays a significant role in the pathophysiology of metabolic syndrome. Activated macrophages in adipose tissue secrete pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), which further disrupt normal lipoprotein metabolism and exacerbate insulin resistance [29]. The interplay between inflammation and lipid metabolism creates a vicious cycle that promotes the progression of metabolic syndrome [30].

Moreover, the dysregulation of the adenosine monophosphate-activated protein kinase (AMPK) pathway is a crucial mechanism linking lipid metabolism abnormalities to metabolic syndrome. AMPK is a key regulator of energy homeostasis and lipid metabolism; its dysregulation can lead to increased malonyl-CoA levels, which alter intracellular fatty acid partitioning and promote lipid accumulation [31].

In summary, the mechanisms of dyslipidemia and lipid metabolism in metabolic syndrome are multifaceted, involving insulin resistance, dietary influences, microRNA regulation, chronic inflammation, and the dysregulation of critical metabolic pathways such as AMPK signaling. Understanding these intricate mechanisms is essential for developing targeted therapeutic strategies to address the lipid abnormalities associated with metabolic syndrome and reduce the risk of cardiovascular diseases and type 2 diabetes.

4 Role of Lifestyle Factors ​

4.1 Diet and Nutrition ​

Metabolic syndrome is a complex pathological state characterized by a cluster of metabolic and cardiovascular abnormalities, including visceral obesity, insulin resistance, dyslipidemia, and hypertension. Various mechanisms contribute to the development of metabolic syndrome, with lifestyle factors, particularly diet and nutrition, playing a significant role.

Dietary intake is one of the critical environmental factors influencing the pathogenesis of metabolic syndrome. The Western diet, characterized by high consumption of refined carbohydrates, sugars, and unhealthy fats, has been linked to increased prevalence of this syndrome. Such dietary patterns lead to obesity, which is a major aetiological factor in metabolic syndrome, as it exacerbates insulin resistance and alters hormone and cytokine profiles produced by adipose tissue [32].

Maternal nutrition during pregnancy also plays a crucial role in the development of metabolic syndrome in offspring. Inadequate maternal nutrition can lead to intrauterine growth retardation, which, when followed by excess nutrition postnatally, creates a mismatch that predisposes individuals to metabolic syndrome. This phenomenon highlights the importance of nutritional programming, where early-life dietary conditions affect metabolic health later in life [33].

Furthermore, dietary fibers have been shown to influence the metabolic syndrome positively. Their intake can help manage body weight, regulate glucose and lipid homeostasis, and improve insulin sensitivity. Different types of dietary fibers interact with the body in various ways, contributing to the regulation of inflammation markers that are significant in the pathogenesis of metabolic syndrome [34].

Additionally, epigenetic modifications induced by diet are emerging as important mechanisms in the development of metabolic syndrome. These modifications can alter gene expression without changing the DNA sequence, thereby influencing the pathophysiological processes associated with obesity and insulin resistance. For instance, dietary-related microbiota and their metabolites may lead to epigenetic changes that contribute to the insulin-resistant state [10].

In summary, the mechanisms underlying metabolic syndrome are multifaceted, with lifestyle factors such as diet and nutrition playing a pivotal role. The interactions between dietary habits, maternal nutrition, and epigenetic modifications illustrate the complexity of this syndrome and underscore the need for comprehensive strategies targeting lifestyle changes to prevent and manage metabolic syndrome effectively.

4.2 Physical Activity and Sedentary Behavior ​

Metabolic syndrome is characterized by a cluster of metabolic and cardiovascular abnormalities, including visceral obesity, insulin resistance, dyslipidemia, and hypertension, which predispose individuals to serious health complications such as diabetes, cardiovascular disease, and chronic kidney disease. Lifestyle factors, particularly physical activity and sedentary behavior, play a crucial role in the development and management of metabolic syndrome.

Physical activity is essential for maintaining energy balance and promoting metabolic health. It helps in reducing body weight, improving insulin sensitivity, and enhancing lipid profiles. Regular moderate-to-vigorous physical activity (MVPA) is associated with a decreased risk of developing metabolic syndrome. In a study analyzing data from the National Health and Nutrition Examination Survey, it was found that the average daily sedentary behavior (SB) time was 8.1 hours, with a prevalence of metabolic syndrome at 19%. The study indicated a linear relationship between daily SB time and the metabolic syndrome, characterized by an odds ratio of 1.09 for each additional hour of SB[35]. This suggests that increased sedentary time correlates with higher risks of metabolic syndrome components such as high triglycerides, low HDL cholesterol, and elevated fasting glucose levels[35].

Sedentary behavior, defined as any waking activity characterized by an energy expenditure ≤ 1.5 metabolic equivalents, has been identified as an independent risk factor for cardiometabolic health. Prolonged periods of inactivity are associated with disturbances in carbohydrate and lipid metabolism, increased oxidative stress, and chronic inflammation, all of which contribute to the development of metabolic syndrome[36]. The cumulative effect of sedentary behavior on metabolic health underscores the importance of lifestyle interventions aimed at reducing inactivity.

Furthermore, the relationship between sedentary behavior and metabolic syndrome can be modulated by dietary habits. In western societies, where sedentary lifestyles are prevalent, high-calorie diets lacking essential nutrients exacerbate the risk of developing metabolic syndrome[37]. The interplay between nutrition and physical inactivity highlights the need for comprehensive lifestyle modifications that include both increased physical activity and improved dietary practices.

Psychosocial stress also plays a significant role in the metabolic syndrome's etiology. Stress can lead to unhealthy coping mechanisms, such as overeating or reduced physical activity, further compounding the risks associated with metabolic syndrome[38]. Understanding these psychosocial factors is essential for developing effective prevention and treatment strategies.

In conclusion, lifestyle factors, particularly physical activity and sedentary behavior, are integral to the mechanisms underlying metabolic syndrome. The evidence suggests that increasing physical activity and reducing sedentary time can significantly mitigate the risks associated with metabolic syndrome, highlighting the need for targeted lifestyle interventions to improve cardiometabolic health outcomes.

4.3 Obesity and Body Composition ​

Metabolic syndrome is characterized by a cluster of interrelated metabolic and cardiovascular derangements, including visceral obesity, insulin resistance, dyslipidemia, hypertension, and an increased risk for cardiovascular diseases and type 2 diabetes. The underlying mechanisms of metabolic syndrome are multifactorial, involving a complex interplay of genetic, environmental, and lifestyle factors.

One of the primary contributors to the development of metabolic syndrome is obesity, particularly central obesity, which is defined by an increased abdominal circumference. This condition is recognized as a significant risk factor for the syndrome, with studies indicating that the global rise in obesity correlates with an increase in the incidence of metabolic syndrome [39]. The accumulation of adipose tissue, especially visceral fat, leads to insulin resistance, which is a hallmark of metabolic syndrome. Insulin resistance, in turn, is associated with hyperglycemia, dyslipidemia, and hypertension, further exacerbating cardiovascular risks [10].

In addition to obesity, lifestyle factors such as diet and physical activity play crucial roles in the pathogenesis of metabolic syndrome. A sedentary lifestyle combined with a high-fat diet is a significant risk factor that contributes to the development of obesity and metabolic dysfunction [38]. The quality of dietary intake, including the types of fats consumed, can influence metabolic health. Lifestyle modification strategies that focus on caloric restriction and increased physical activity have been shown to reverse metabolic risk factors associated with metabolic syndrome [4].

Moreover, the relationship between psychosocial stress and nutrition is important to consider. Chronic stress can lead to unhealthy eating behaviors, which may further promote obesity and metabolic syndrome [38]. The psychological aspects of lifestyle, including stress management, are therefore essential components in the prevention and treatment of metabolic syndrome.

Epigenetic modifications also play a significant role in the mechanisms of metabolic syndrome. Research indicates that environmental factors, including diet and physical activity, can induce reversible changes in gene expression without altering the DNA sequence. These epigenetic changes may contribute to the development of insulin resistance and other metabolic abnormalities associated with the syndrome [10].

In summary, the mechanisms underlying metabolic syndrome are complex and multifactorial, with obesity and body composition being central to its development. Lifestyle factors, particularly diet and physical activity, significantly influence these mechanisms. Addressing these lifestyle factors through interventions focused on dietary modifications and increased physical activity is crucial for the prevention and management of metabolic syndrome.

5 Genetic and Epigenetic Influences ​

5.1 Genetic Predisposition ​

Metabolic syndrome is characterized by a cluster of metabolic disorders, including insulin resistance, hypertension, dyslipidemia, and obesity, which together increase the risk of cardiovascular disease and type 2 diabetes. The mechanisms underlying metabolic syndrome are multifaceted, involving both genetic predisposition and epigenetic influences that interact with environmental factors.

Genetic predisposition plays a crucial role in the development of metabolic syndrome. Certain genetic variants can affect an individual's susceptibility to insulin resistance and other metabolic abnormalities. However, genetic factors alone do not fully explain the rising prevalence of metabolic syndrome, particularly in the context of environmental changes and lifestyle factors. Studies have shown that metabolic disorders are complex traits influenced by multiple genes, and the heritability of these conditions is often only partial, indicating significant contributions from non-genetic factors[40].

Epigenetic mechanisms have emerged as key players in linking environmental exposures to metabolic outcomes. These mechanisms include DNA methylation, histone modifications, chromatin remodeling, and the action of non-coding RNAs. They allow for reversible modifications of gene expression without altering the underlying DNA sequence, thus playing a pivotal role in the pathophysiology of metabolic syndrome[41].

Research indicates that epigenetic modifications can be influenced by various factors, including diet, physical activity, and exposure to environmental toxins. For instance, dietary components have been shown to induce epigenetic changes that can significantly affect metabolic pathways, contributing to the development of insulin resistance and obesity[42]. Nutritional epigenetics, or nutrigenomics, explores how specific dietary components can modulate gene expression and potentially reverse epigenetic modifications associated with metabolic disorders[43].

Furthermore, the concept of "gestational programming" highlights how maternal nutrition and environmental exposures during pregnancy can lead to epigenetic alterations in offspring, predisposing them to metabolic syndrome later in life[44]. This suggests that epigenetic changes can be transmitted across generations, emphasizing the importance of both genetic and epigenetic factors in the intergenerational transmission of metabolic disease risk[45].

In summary, the mechanisms of metabolic syndrome involve a complex interplay between genetic predisposition and epigenetic modifications influenced by environmental factors. Understanding these mechanisms is crucial for developing targeted interventions and prevention strategies for metabolic syndrome and its associated health risks.

5.2 Epigenetic Modifications and Environmental Interactions ​

Metabolic syndrome is a complex cluster of conditions, including insulin resistance, hypertension, dyslipidemia, and abdominal obesity, which collectively increase the risk of cardiovascular disease and type 2 diabetes mellitus (T2DM). The mechanisms underlying metabolic syndrome involve intricate interactions between genetic predispositions and environmental factors, particularly through epigenetic modifications.

Epigenetic modifications refer to reversible changes in gene expression that do not involve alterations to the underlying DNA sequence. These modifications can be influenced by various environmental factors, including diet, physical activity, and exposure to endocrine disruptors. The most common types of epigenetic modifications include DNA methylation, histone modifications, and chromatin remodeling, which collectively regulate gene expression and cellular function.

Recent research has highlighted the role of epigenetic mechanisms in the pathogenesis of metabolic syndrome. For instance, specific epigenetic changes, such as altered DNA methylation patterns and histone modifications, have been linked to the development of obesity and insulin resistance. Stols-Gonçalves et al. (2019) emphasized that "epigenetic modifications induced by diet-related microbiota or metabolites possibly contribute to the insulin-resistant state"[10]. This indicates that the gut microbiome and dietary components can induce epigenetic changes that predispose individuals to metabolic dysfunction.

Furthermore, the concept of "gestational programming" underscores the impact of maternal nutrition and environmental exposures during pregnancy on the epigenome of offspring. Desai et al. (2015) reported that "nutrient and environmental agent exposures... during pregnancy may affect fetal/newborn development resulting in offspring obesity and obesity-associated metabolic abnormalities"[44]. This transgenerational transmission of epigenetic modifications highlights the long-lasting effects of early environmental exposures on metabolic health.

Dietary factors play a crucial role in shaping the epigenetic landscape associated with metabolic syndrome. Park et al. (2017) noted that "dietary factor-dependent epigenetic modifications can significantly affect genome stability and the expression of mRNA and proteins, which are involved in metabolic dysfunction"[42]. This suggests that specific nutrients can modulate gene expression through epigenetic mechanisms, potentially reversing or exacerbating the symptoms of metabolic syndrome.

Moreover, the interaction between genetic factors and epigenetic modifications is essential for understanding the individual variability in susceptibility to metabolic syndrome. Genetic predispositions can influence how environmental factors, including diet, impact epigenetic changes. For instance, Roche et al. (2005) highlighted the importance of gene-environment interactions, stating that "the expression of... metabolic syndrome factors has been found to be the result of complex interactions between genetic and environmental factors"[32].

In conclusion, the mechanisms of metabolic syndrome are multifaceted, involving genetic influences and epigenetic modifications shaped by environmental interactions. Understanding these complex relationships is crucial for developing targeted interventions and prevention strategies aimed at mitigating the impact of metabolic syndrome on public health. The ongoing exploration of epigenetic mechanisms and their reversible nature holds promise for novel therapeutic approaches in addressing obesity and related metabolic disorders.

6 Emerging Research Areas ​

6.1 Gut Microbiome and Metabolic Health ​

Metabolic syndrome is characterized by a cluster of conditions including central obesity, dysglycemia, dyslipidemia, and hypertension, which significantly increase the risk of developing cardiovascular diseases and type 2 diabetes. Recent research highlights the critical role of the gut microbiome in the pathophysiology of metabolic syndrome, revealing several mechanisms through which gut microbiota influences metabolic health.

One of the primary mechanisms is the interaction between gut microbiota and host metabolism, particularly through the production of short-chain fatty acids (SCFAs) from the fermentation of dietary fibers. SCFAs such as acetate, propionate, and butyrate have been shown to positively influence various metabolic processes, including satiety, glucose homeostasis, and lipid metabolism, thereby playing a protective role against metabolic disorders like type 2 diabetes and hypertension [46]. The gut microbiota also modulates the immune response and maintains gut barrier integrity, which are crucial for preventing systemic inflammation that contributes to metabolic dysfunction [47].

Dysbiosis, or the imbalance of gut microbiota, has been implicated in the development of metabolic syndrome. It can lead to increased gut permeability, allowing for the translocation of bacterial metabolites into the bloodstream, which may trigger chronic low-grade inflammation and insulin resistance [48]. The innate immune response to microbial components, such as lipopolysaccharides, further exacerbates inflammation, creating a vicious cycle that promotes metabolic disorders [49].

Moreover, the gut microbiome influences energy homeostasis by affecting how the host extracts energy from non-digestible carbohydrates. This interaction can alter the metabolic pathways involved in energy storage and utilization, contributing to obesity and its related complications [50]. The dysregulated gut microbiota may also interfere with the renin-angiotensin system, which plays a critical role in blood pressure regulation, thereby linking gut health to hypertension [51].

Therapeutically, targeting the gut microbiome presents a promising avenue for managing metabolic syndrome. Interventions such as the administration of probiotics, prebiotics, and dietary modifications aim to restore a healthy gut microbiota composition, which could ameliorate the metabolic disturbances associated with this syndrome [47][52]. Additionally, recent studies suggest that fecal microbiota transplantation may serve as a novel treatment strategy by reintroducing beneficial microbial communities into the gut [53].

In summary, the gut microbiome is a significant factor in the pathogenesis of metabolic syndrome, operating through various mechanisms that include modulation of immune responses, regulation of energy metabolism, and maintenance of gut barrier integrity. Ongoing research continues to elucidate these complex interactions, paving the way for innovative microbiota-targeted therapies to mitigate the burden of metabolic syndrome and its associated health complications.

6.2 Hormonal Regulation and Endocrine Disruptors ​

Metabolic syndrome is characterized by a cluster of metabolic and vascular abnormalities, including insulin resistance, hypertension, dyslipidemia, and central obesity, which collectively increase the risk of cardiovascular disease and type 2 diabetes. The mechanisms underlying metabolic syndrome are complex and multifactorial, involving genetic, environmental, and hormonal factors.

One significant aspect of metabolic syndrome is the role of hormonal regulation. Insulin resistance is a central feature of this condition, where the biological actions of insulin are diminished, leading to compensatory hyperinsulinemia. Various hormones influence insulin action, either enhancing or reducing its effects. For instance, the glucocorticoid hormone and the growth hormone-insulin-like growth factor (IGF-1) axis are critical pathways that modulate insulin sensitivity and contribute to the pathogenesis of metabolic syndrome [54].

Additionally, the secretion of various factors from visceral adipose tissue plays a crucial role in metabolic dysregulation. These factors can affect glucose metabolism not only in traditional insulin-sensitive tissues but also in non-traditional tissues, such as the cardiovascular system [13]. This interrelationship underscores the importance of hormonal signaling in the context of metabolic syndrome.

Emerging research has also highlighted the impact of endocrine disruptors—environmental chemicals that can interfere with hormonal systems—on metabolic health. Epidemiological studies suggest that exposure to these disruptors is linked to the development of metabolic diseases, including obesity and diabetes. They can affect insulin secretion and impair insulin signaling pathways, contributing to the insulin-resistant state characteristic of metabolic syndrome [55].

Circadian rhythms have also been implicated in the pathogenesis of metabolic syndrome. Disruption of circadian systems can disturb neuroendocrine pathways in the hypothalamus, which are essential for regulating feeding behavior and energy metabolism. This disruption can lead to dysregulation of lipid and glucose homeostasis, inflammation, and cardiovascular function [56].

In summary, the mechanisms of metabolic syndrome are multifaceted, involving hormonal regulation, the influence of endocrine disruptors, and circadian disruptions. These factors collectively contribute to the pathophysiology of metabolic syndrome, underscoring the need for comprehensive approaches in understanding and managing this complex condition.

7 Conclusion ​

This review highlights the intricate and multifaceted mechanisms underlying metabolic syndrome (MetS), emphasizing the central roles of insulin resistance, inflammation, dyslipidemia, and lifestyle factors. The interplay between genetic predispositions and environmental influences, particularly diet and physical activity, is crucial in the pathogenesis of MetS. Current research underscores the significance of the gut microbiome and hormonal regulation in metabolic health, revealing novel therapeutic avenues for intervention. The rising prevalence of MetS necessitates urgent public health initiatives aimed at promoting healthier lifestyles and targeted interventions to mitigate its impact. Future research should focus on elucidating the complex interactions between these factors, exploring innovative treatment strategies, and understanding the long-term effects of early-life exposures on metabolic health. Addressing these challenges through a multidisciplinary approach is essential for effectively combating the growing public health crisis posed by metabolic syndrome.

References ​

  • [1] Josep Redon;Renata Cifkova;Stephane Laurent;Peter Nilsson;Krzysztof Narkiewicz;Serap Erdine;Giuseppe Mancia; . The metabolic syndrome in hypertension: European society of hypertension position statement.. Journal of hypertension(IF=4.1). 2008. PMID:18806611. DOI: 10.1097/HJH.0b013e328302ca38.
  • [2] Josep Redon;Renata Cifkova;Stephane Laurent;Peter Nilsson;Krzysztof Narkiewicz;Serap Erdine;Giuseppe Mancia. Mechanisms of hypertension in the cardiometabolic syndrome.. Journal of hypertension(IF=4.1). 2009. PMID:19262221. DOI: 10.1097/HJH.0b013e32831e13e5.
  • [3] K Minehira;L Tappy. Dietary and lifestyle interventions in the management of the metabolic syndrome: present status and future perspective.. European journal of clinical nutrition(IF=3.3). 2002. PMID:12494312. DOI: 10.1038/sj.ejcn.1601645.
  • [4] Scott M Grundy. Metabolic syndrome update.. Trends in cardiovascular medicine(IF=9.0). 2016. PMID:26654259. DOI: .
  • [5] Andrew M James;Yvonne Collins;Angela Logan;Michael P Murphy. Mitochondrial oxidative stress and the metabolic syndrome.. Trends in endocrinology and metabolism: TEM(IF=12.6). 2012. PMID:22831852. DOI: 10.1016/j.tem.2012.06.008.
  • [6] Dongsheng Cai;Tiewen Liu. Inflammatory cause of metabolic syndrome via brain stress and NF-κB.. Aging(IF=3.9). 2012. PMID:22328600. DOI: 10.18632/aging.100431.
  • [7] Sven M Francque. Towards precision medicine in non-alcoholic fatty liver disease.. Reviews in endocrine & metabolic disorders(IF=8.0). 2023. PMID:37477772. DOI: 10.1007/s11154-023-09820-6.
  • [8] Scott M Grundy. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds.. Journal of the American College of Cardiology(IF=22.3). 2006. PMID:16545636. DOI: 10.1016/j.jacc.2005.11.046.
  • [9] Karina Sánchez-Alegría;Carlos Ernesto Bastián-Eugenio;Luis Vaca;Clorinda Arias. Palmitic acid induces insulin resistance by a mechanism associated with energy metabolism and calcium entry in neuronal cells.. FASEB journal : official publication of the Federation of American Societies for Experimental Biology(IF=4.2). 2021. PMID:34110637. DOI: 10.1096/fj.202100243R.
  • [10] Daniela Stols-Gonçalves;Luca Schiliró Tristão;Peter Henneman;Max Nieuwdorp. Epigenetic Markers and Microbiota/Metabolite-Induced Epigenetic Modifications in the Pathogenesis of Obesity, Metabolic Syndrome, Type 2 Diabetes, and Non-alcoholic Fatty Liver Disease.. Current diabetes reports(IF=6.4). 2019. PMID:31044315. DOI: 10.1007/s11892-019-1151-4.
  • [11] Chien-Ning Hsu;Chih-Yao Hou;Wei-Hsuan Hsu;You-Lin Tain. Early-Life Origins of Metabolic Syndrome: Mechanisms and Preventive Aspects.. International journal of molecular sciences(IF=4.9). 2021. PMID:34769303. DOI: 10.3390/ijms222111872.
  • [12] José Ordovas. Diet/genetic interactions and their effects on inflammatory markers.. Nutrition reviews(IF=4.9). 2007. PMID:18240549. DOI: 10.1111/j.1753-4887.2007.tb00363.x.
  • [13] Kunal Chaudhary;J P Buddineni;Ravi Nistala;Adam Whaley-Connell. Resistant hypertension in the high-risk metabolic patient.. Current diabetes reports(IF=6.4). 2011. PMID:20941645. DOI: 10.1007/s11892-010-0155-x.
  • [14] A Avogaro. Insulin resistance: trigger or concomitant factor in the metabolic syndrome.. Panminerva medica(IF=4.3). 2006. PMID:16633326. DOI: .
  • [15] Rebecca Parish;Kitt Falk Petersen. Mitochondrial dysfunction and type 2 diabetes.. Current diabetes reports(IF=6.4). 2005. PMID:15929863. DOI: 10.1007/s11892-005-0006-3.
  • [16] David B Savage;Kitt F Petersen;Gerald I Shulman. Mechanisms of insulin resistance in humans and possible links with inflammation.. Hypertension (Dallas, Tex. : 1979)(IF=8.2). 2005. PMID:15824195. DOI: 10.1161/01.HYP.0000163475.04421.e4.
  • [17] Jerry R Colca. Insulin sensitizers may prevent metabolic inflammation.. Biochemical pharmacology(IF=5.6). 2006. PMID:16472781. DOI: 10.1016/j.bcp.2006.01.002.
  • [18] Audrey E Brown;Mark Walker. Genetics of Insulin Resistance and the Metabolic Syndrome.. Current cardiology reports(IF=3.3). 2016. PMID:27312935. DOI: 10.1007/s11886-016-0755-4.
  • [19] Nasser Mikhail. The metabolic syndrome: insulin resistance.. Current hypertension reports(IF=5.1). 2009. PMID:19278606. DOI: 10.1007/s11906-009-0027-4.
  • [20] Hema S Bagry;Sreekrishna Raghavendran;Franco Carli. Metabolic syndrome and insulin resistance: perioperative considerations.. Anesthesiology(IF=9.1). 2008. PMID:18292688. DOI: 10.1097/ALN.0b013e3181649314.
  • [21] Shinichi Saitoh;Koen Van Wijk;Osamu Nakajima. Crosstalk between Metabolic Disorders and Immune Cells.. International journal of molecular sciences(IF=4.9). 2021. PMID:34576181. DOI: 10.3390/ijms221810017.
  • [22] Sudarshana Purkayastha;Dongsheng Cai. Neuroinflammatory basis of metabolic syndrome.. Molecular metabolism(IF=6.6). 2013. PMID:24327952. DOI: 10.1016/j.molmet.2013.09.005.
  • [23] Mari van de Vyver. Immunology of chronic low-grade inflammation: relationship with metabolic function.. The Journal of endocrinology(IF=3.9). 2023. PMID:36688876. DOI: .
  • [24] Joo-Hui Han. Immuno-metabolic diseases and therapeutics: molecular mechanisms via inflammasome signaling.. Cell communication and signaling : CCS(IF=8.9). 2025. PMID:40830886. DOI: 10.1186/s12964-025-02368-9.
  • [25] Patrice Therond. Catabolism of lipoproteins and metabolic syndrome.. Current opinion in clinical nutrition and metabolic care(IF=3.5). 2009. PMID:19474714. DOI: 10.1097/MCO.0b013e32832c5a12.
  • [26] Ana Maria Lottenberg;Milessa da Silva Afonso;Maria Silvia Ferrari Lavrador;Roberta Marcondes Machado;Edna Regina Nakandakare. The role of dietary fatty acids in the pathology of metabolic syndrome.. The Journal of nutritional biochemistry(IF=4.9). 2012. PMID:22749135. DOI: 10.1016/j.jnutbio.2012.03.004.
  • [27] Patricia Christian;Qiaozhu Su. MicroRNA regulation of mitochondrial and ER stress signaling pathways: implications for lipoprotein metabolism in metabolic syndrome.. American journal of physiology. Endocrinology and metabolism(IF=3.1). 2014. PMID:25184990. DOI: 10.1152/ajpendo.00194.2014.
  • [28] Nathan L Price;Cristina M Ramírez;Carlos Fernández-Hernando. Relevance of microRNA in metabolic diseases.. Critical reviews in clinical laboratory sciences(IF=5.5). 2014. PMID:25034902. DOI: 10.3109/10408363.2014.937522.
  • [29] Daynene Vykoukal;Mark G Davies. Vascular biology of metabolic syndrome.. Journal of vascular surgery(IF=3.6). 2011. PMID:21439758. DOI: 10.1016/j.jvs.2011.01.003.
  • [30] Peter J Meikle;Michael J Christopher. Lipidomics is providing new insight into the metabolic syndrome and its sequelae.. Current opinion in lipidology(IF=4.6). 2011. PMID:21378565. DOI: 10.1097/MOL.0b013e3283453dbe.
  • [31] Neil B Ruderman;Asish K Saha. Metabolic syndrome: adenosine monophosphate-activated protein kinase and malonyl coenzyme A.. Obesity (Silver Spring, Md.)(IF=4.7). 2006. PMID:16642960. DOI: 10.1038/oby.2006.279.
  • [32] Helen M Roche;Catherine Phillips;Michael J Gibney. The metabolic syndrome: the crossroads of diet and genetics.. The Proceedings of the Nutrition Society(IF=4.5). 2005. PMID:16048671. DOI: 10.1079/pns2005445.
  • [33] Ramakrishnan Lakshmy. Metabolic syndrome: role of maternal undernutrition and fetal programming.. Reviews in endocrine & metabolic disorders(IF=8.0). 2013. PMID:24005943. DOI: 10.1007/s11154-013-9266-4.
  • [34] Milagros Galisteo;Juan Duarte;Antonio Zarzuelo. Effects of dietary fibers on disturbances clustered in the metabolic syndrome.. The Journal of nutritional biochemistry(IF=4.9). 2008. PMID:17618108. DOI: 10.1016/j.jnutbio.2007.02.009.
  • [35] Keith P Gennuso;Ronald E Gangnon;Keith M Thraen-Borowski;Lisa H Colbert. Dose-response relationships between sedentary behaviour and the metabolic syndrome and its components.. Diabetologia(IF=10.2). 2015. PMID:25476524. DOI: 10.1007/s00125-014-3453-z.
  • [36] Wouter M A Franssen;Ine Nieste;Kenneth Verboven;Bert O Eijnde. Sedentary behaviour and cardiometabolic health: Integrating the potential underlying molecular health aspects.. Metabolism: clinical and experimental(IF=11.9). 2025. PMID:40483777. DOI: 10.1016/j.metabol.2025.156320.
  • [37] Atif B Awad;Lini Alappat;Michael Valerio. Vitamin d and metabolic syndrome risk factors: evidence and mechanisms.. Critical reviews in food science and nutrition(IF=8.8). 2012. PMID:22059957. DOI: 10.1080/10408391003785458.
  • [38] Gertjan van Dijk;Bauke Buwalda. Neurobiology of the metabolic syndrome: an allostatic perspective.. European journal of pharmacology(IF=4.7). 2008. PMID:18395710. DOI: 10.1016/j.ejphar.2007.11.079.
  • [39] Bogdan M Tarcău;Laura G Vicaș;Lorena Filip;Florin Maghiar;Mircea Șandor;Annamaria Pallag;Tunde Jurca;Mariana Eugenia Mureșan;Eleonora Marian. Emerging Perspectives on the Set of Conditions That Lead to the Emergence of Metabolic Syndrome.. Journal of personalized medicine(IF=3.0). 2023. PMID:38248733. DOI: 10.3390/jpm14010032.
  • [40] Ilaria Panzeri;John Andrew Pospisilik. Epigenetic control of variation and stochasticity in metabolic disease.. Molecular metabolism(IF=6.6). 2018. PMID:29909200. DOI: 10.1016/j.molmet.2018.05.010.
  • [41] Yan-Lin Wu;Zheng-Jun Lin;Chang-Chun Li;Xiao Lin;Su-Kang Shan;Bei Guo;Ming-Hui Zheng;Fuxingzi Li;Ling-Qing Yuan;Zhi-Hong Li. Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study.. Signal transduction and targeted therapy(IF=52.7). 2023. PMID:36864020. DOI: 10.1038/s41392-023-01333-7.
  • [42] Jae-Ho Park;Soon-Hee Kim;Myeong Soo Lee;Myung-Sunny Kim. Epigenetic modification by dietary factors: Implications in metabolic syndrome.. Molecular aspects of medicine(IF=10.3). 2017. PMID:28216432. DOI: 10.1016/j.mam.2017.01.008.
  • [43] Nidhi Chaudhary;Kiran Kumar Nakka;Nilanjana Maulik;Samit Chattopadhyay. Epigenetic manifestation of metabolic syndrome and dietary management.. Antioxidants & redox signaling(IF=6.1). 2012. PMID:22229755. DOI: 10.1089/ars.2011.4387.
  • [44] M Desai;J K Jellyman;M G Ross. Epigenomics, gestational programming and risk of metabolic syndrome.. International journal of obesity (2005)(IF=3.8). 2015. PMID:25640766. DOI: 10.1038/ijo.2015.13.
  • [45] Lei Su;Mary Elizabeth Patti. Paternal Nongenetic Intergenerational Transmission of Metabolic Disease Risk.. Current diabetes reports(IF=6.4). 2019. PMID:31127415. DOI: 10.1007/s11892-019-1163-0.
  • [46] F Fava;L Rizzetto;K M Tuohy. Gut microbiota and health: connecting actors across the metabolic system.. The Proceedings of the Nutrition Society(IF=4.5). 2019. PMID:30561288. DOI: 10.1017/S0029665118002719.
  • [47] Emmanuel Henry Ezenabor;Aishat Abimbola Adeyemi;Oluyomi Stephen Adeyemi. Gut Microbiota and Metabolic Syndrome: Relationships and Opportunities for New Therapeutic Strategies.. Scientifica(IF=3.1). 2024. PMID:39041052. DOI: 10.1155/2024/4222083.
  • [48] Piero Portincasa;Mohamad Khalil;Annarita Graziani;Gema Frühbeck;Gyorgy Baffy;Gabriella Garruti;Agostino Di Ciaula;Leonilde Bonfrate. Gut microbes in metabolic disturbances. Promising role for therapeutic manipulations?. European journal of internal medicine(IF=6.1). 2024. PMID:37802720. DOI: 10.1016/j.ejim.2023.10.002.
  • [49] Kristina Harris;Amira Kassis;Geneviève Major;Chieh J Chou. Is the gut microbiota a new factor contributing to obesity and its metabolic disorders?. Journal of obesity(IF=3.9). 2012. PMID:22315672. DOI: 10.1155/2012/879151.
  • [50] Mohsen Mazidi;Peyman Rezaie;Andre Pascal Kengne;Majid Ghayour Mobarhan;Gordon A Ferns. Gut microbiome and metabolic syndrome.. Diabetes & metabolic syndrome(IF=3.4). 2016. PMID:26916014. DOI: .
  • [51] Francesca D'Aversa;Annalisa Tortora;Gianluca Ianiro;Francesca Romana Ponziani;Brigida Eleonora Annicchiarico;Antonio Gasbarrini. Gut microbiota and metabolic syndrome.. Internal and emergency medicine(IF=3.8). 2013. PMID:23468402. DOI: 10.1007/s11739-013-0916-z.
  • [52] Yong-Wei Xu;Jun Tian;Yan Song;Ba-Cui Zhang;Jing Wang. Metabolic syndrome's new therapy: Supplement the gut microbiome.. World journal of diabetes(IF=4.6). 2024. PMID:38680700. DOI: 10.4239/wjd.v15.i4.793.
  • [53] Mc Anto Antony;Aniqa Chowdhury;Dinesh Edem;Rishi Raj;Priyanshu Nain;Mansi Joglekar;Vipin Verma;Ravi Kant. Gut microbiome supplementation as therapy for metabolic syndrome.. World journal of diabetes(IF=4.6). 2023. PMID:37970133. DOI: 10.4239/wjd.v14.i10.1502.
  • [54] C D Byrne. Programming other hormones that affect insulin.. British medical bulletin(IF=5.2). 2001. PMID:11809624. DOI: 10.1093/bmb/60.1.153.
  • [55] Robert M Sargis. The hijacking of cellular signaling and the diabetes epidemic: mechanisms of environmental disruption of insulin action and glucose homeostasis.. Diabetes & metabolism journal(IF=8.5). 2014. PMID:24627823. DOI: 10.4093/dmj.2014.38.1.13.
  • [56] E Maury;H K Hong;J Bass. Circadian disruption in the pathogenesis of metabolic syndrome.. Diabetes & metabolism(IF=4.7). 2014. PMID:24433933. DOI: .

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Metabolic Syndrome · Insulin Resistance · Chronic Inflammation · Dyslipidemia · Gut Microbiome

© 2025 MaltSci